Emily S Van Laar Selected Research

Therapeutics

7/2008

Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Emily S Van Laar Research Topics

Disease

6	Neoplasms (Cancer) 01/2015 - 01/2004
1	Vomiting 01/2015
1	Nausea 01/2015
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 07/2009
1	Colonic Neoplasms (Colon Cancer) 09/2004
1	Ovarian Neoplasms (Ovarian Cancer) 09/2004
1	Prostatic Neoplasms (Prostate Cancer) 04/2004
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2004

Drug/Important Bio-Agent (IBA)

4	irofulvenIBA 07/2008 - 01/2004
1	acylfulveneIBA 01/2010
1	Cytotoxins (Cytolysins)IBA 01/2010
1	Peptides (Polypeptides)IBA 01/2010
1	Galectin 1 (LGALS1)IBA 01/2010
1	Decitabine FDA Link 07/2009
1	compound 0118IBA 07/2008
1	Angiogenesis InhibitorsIBA 07/2008
1	Checkpoint Kinase 1IBA 09/2004
1	Phosphotransferases (Kinase)IBA 09/2004
1	AndrogensIBA 04/2004
1	Mitoxantrone (Novantrone)FDA LinkGeneric 04/2004
1	Antineoplastic Agents (Antineoplastics)IBA 04/2004
1	Hormones (Hormone)IBA 04/2004
1	Docetaxel (Taxotere)FDA Link 04/2004
1	Gemcitabine FDA Link 01/2004

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2015
1	Therapeutics 07/2008